1. Scrip
  2. >>Business
  3. >>Financing

With $120m, HI-Bio Aims To Rapidly Prove Approach To Immune-Mediated Diseases

Phase Ib/IIa Trials To Read Out Next Year

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Human Immunology Biosciences (HI-Bio) launched with $120m and two candidates from MorphoSys, including the CD38 inhibitor felzartamab already in the clinic for immune-mediated kidney diseases.

Venture capital or financial support for startup and entrepreneur company
HI-Bio connected with new investor Jeito in its latest financing • Source: Shutterstock

Human Immunology Biosciences, Inc. (HI-Bio) made a splash over the summer as an unknown start-up that agreed to license two clinical-stage monoclonal antibodies from MorphoSys AG under a deal that could amount to as much as $1bn in milestone fees for the German firm. Now, HI-Bio has come out of stealth mode with $120m in initial funding and plans to rapidly validate its approach to immune-mediated diseases, first with the MorphoSys-discovered CD38 inhibitor felzartamab in two kidney diseases.

South San Francisco-based HI-Bio CEO Travis Murdoch is a physician-scientist with experience treating immune-mediated diseases – particularly, inflammatory bowel disease...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.